Evotec (NASDAQ:EVO) Upgraded to Buy by Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft upgraded shares of Evotec (NASDAQ:EVO) from a hold rating to a buy rating in a research report report published on Friday morning, MarketBeat reports.

Separately, Royal Bank of Canada upgraded shares of Evotec from a sector perform rating to an outperform rating in a report on Thursday, January 18th.

Evotec Price Performance

Evotec stock opened at $7.25 on Friday. Evotec has a fifty-two week low of $6.83 and a fifty-two week high of $13.49. The firm has a fifty day moving average price of $7.42 and a two-hundred day moving average price of $8.79.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Mubadala Investment Co PJSC bought a new stake in Evotec in the fourth quarter valued at about $53,931,000. OLD Mission Capital LLC acquired a new position in shares of Evotec during the fourth quarter worth approximately $141,000. Optiver Holding B.V. lifted its position in shares of Evotec by 643.1% during the fourth quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock worth $945,000 after purchasing an additional 69,936 shares in the last quarter. Finally, Quadrant Capital Group LLC acquired a new position in Evotec in the fourth quarter valued at approximately $25,000. Institutional investors own 5.81% of the company’s stock.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.